Moomoo AI 已提取核心信息
Connect Biopharma Holdings Limited announced on February 12, 2024, the appointment of James Zuie-chin Huang, M.B.A., as a new member of its Board of Directors. Huang brings over three decades of biotech experience to the table, having founded Panacea Venture and served in senior roles at various prestigious firms and companies, including Kleiner Perkins China, Vivo Ventures, and Anesiva, Inc. His previous board memberships include Casi Pharmaceuticals, Windtree Therapeutics, and Alaunos Therapeutics, and he currently serves on the board of Kindstar Globalgene Technology. Huang's educational background includes an M.B.A. from Stanford and a B.S. in chemical engineering from UC Berkeley. The Board has confirmed Huang as an independent director per Nasdaq's listing requirements, and he has entered into the company's standard Indemnification Agreement. There are no disclosed arrangements or transactions involving Huang that would necessitate disclosure under SEC regulations.
Connect Biopharma Holdings Limited announced on February 12, 2024, the appointment of James Zuie-chin Huang, M.B.A., as a new member of its Board of Directors. Huang brings over three decades of biotech experience to the table, having founded Panacea Venture and served in senior roles at various prestigious firms and companies, including Kleiner Perkins China, Vivo Ventures, and Anesiva, Inc. His previous board memberships include Casi Pharmaceuticals, Windtree Therapeutics, and Alaunos Therapeutics, and he currently serves on the board of Kindstar Globalgene Technology. Huang's educational background includes an M.B.A. from Stanford and a B.S. in chemical engineering from UC Berkeley. The Board has confirmed Huang as an independent director per Nasdaq's listing requirements, and he has entered into the company's standard Indemnification Agreement. There are no disclosed arrangements or transactions involving Huang that would necessitate disclosure under SEC regulations.
Connect Biopharma Holdings Limited于2024年2月12日宣布，任命工商管理硕士黄瑞钦为董事会新成员。黄拥有超过三十年的生物技术经验，他创立了Panacea Venture，并在包括克莱纳·珀金斯中国、Vivo Ventures和Anesiva公司在内的多家知名公司和公司担任高级职务。他之前的董事会成员包括卡西制药、Windtree Therapeutics和Alaunos Therapeutics，目前在Kindstar Globalgene Technology的董事会任职。黄的教育背景包括斯坦福大学的工商管理硕士学位和加州大学伯克利分校的化学工程学士学位。根据纳斯达克的上市要求，董事会已确认黄为独立董事，他已经签订了公司的标准赔偿协议。根据美国证券交易委员会的规定，没有任何涉及黄的披露安排或交易需要披露。
Connect Biopharma Holdings Limited于2024年2月12日宣布，任命工商管理硕士黄瑞钦为董事会新成员。黄拥有超过三十年的生物技术经验，他创立了Panacea Venture，并在包括克莱纳·珀金斯中国、Vivo Ventures和Anesiva公司在内的多家知名公司和公司担任高级职务。他之前的董事会成员包括卡西制药、Windtree Therapeutics和Alaunos Therapeutics，目前在Kindstar Globalgene Technology的董事会任职。黄的教育背景包括斯坦福大学的工商管理硕士学位和加州大学伯克利分校的化学工程学士学位。根据纳斯达克的上市要求，董事会已确认黄为独立董事，他已经签订了公司的标准赔偿协议。根据美国证券交易委员会的规定，没有任何涉及黄的披露安排或交易需要披露。
有用
没用